Outlook Therapeutics director buys 122,174 shares
Outlook Therapeutics, Inc. director Sukhtian Faisal Ghiath reported an open-market purchase of 122,174 shares of Common Stock at an average price of $0.4093 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Outlook Therapeutics, Inc. director Sukhtian Faisal Ghiath reported an open-market purchase of 122,174 shares of Common Stock at an average price of $0.4093 per share. Following this transaction, he directly owns a total of 125,574 Common Stock shares.
Insider Trade Summary
Net Buyer: 122,174 shares
Net Buy
1 txn
Insider
Sukhtian Faisal Ghiath
Role
Director
Bought
122,174 shs ($50K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 122,174 | $0.4093 | $50K |
Holdings After Transaction:
Common Stock — 125,574 shares (Direct)
Key Figures
Shares purchased: 122,174 shares
Purchase price: $0.4093 per share
Shares owned after: 125,574 shares
+1 more
4 metrics
Shares purchased
122,174 shares
Open-market purchase of Common Stock
Purchase price
$0.4093 per share
Average price for the reported buy
Shares owned after
125,574 shares
Director’s direct Common Stock holdings post-transaction
Net buy shares
122,174 shares
Net buy activity in the reporting period
Key Terms
open-market purchase, Common Stock, Form 4
3 terms
open-market purchase financial
"reported an open-market purchase of 122,174 shares of Common Stock"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
Common Stock financial
"122,174 shares of Common Stock at an average price of $0.4093"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Form 4 regulatory
"What insider transaction did Outlook Therapeutics (OTLK) report on this Form 4?"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Outlook Therapeutics (OTLK) report on this Form 4?
Outlook Therapeutics director Sukhtian Faisal Ghiath reported buying 122,174 shares of Common Stock in an open-market purchase at $0.4093 per share, increasing his directly held position to 125,574 shares after the transaction.
Who is the insider involved in the latest Outlook Therapeutics (OTLK) Form 4 filing?
The insider is Sukhtian Faisal Ghiath, a director of Outlook Therapeutics, Inc. He reported a single open-market purchase of 122,174 Common Stock shares at $0.4093 per share, bringing his direct holdings to 125,574 shares following the trade.
What are the director’s Outlook Therapeutics (OTLK) holdings after the reported Form 4 transaction?
After the reported open-market purchase, director Sukhtian Faisal Ghiath directly owns 125,574 shares of Outlook Therapeutics Common Stock. This total reflects the addition of 122,174 shares acquired at $0.4093 per share in the disclosed transaction.
Was the Outlook Therapeutics (OTLK) Form 4 transaction a buy or a sell?
The Form 4 shows a buy transaction. Director Sukhtian Faisal Ghiath executed an open-market purchase of 122,174 Common Stock shares at $0.4093 per share, resulting in net buy activity and total direct holdings of 125,574 shares afterward.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates